论文部分内容阅读
目的:观察肾衰Ⅰ号方对慢性肾脏病(CKD)3期脾肾气虚湿瘀证患者的临床疗效。方法:选择符合西医CKD3期诊断标准及中医脾肾气虚湿瘀证诊断标准的患者60例,对照组采用西医基础治疗;治疗组在西医基础治疗上结合口服肾衰Ⅰ号方,两组均连续治疗3个疗程后,分别从临床总疗效、中医症状积分的变化、理化检查指标等方面进行观察评价。结果:治疗组总有效率为77.5%,对照组总有效率为35%;治疗组治疗后BUN和Scr明显下降,eGFR明显升高;临床症状方面,治疗组治疗后症状总积分显著低于治疗前;两组比较,治疗组显著优于对照组(P<0.01)。结论:肾衰Ⅰ号方能有效改善CKD3期脾肾气虚湿瘀证患者的临床症状,改善肾功能,延缓病情的进展。
Objective: To observe the clinical efficacy of Shenshuai No.1 on chronic kidney disease (CKD) stage 3 patients with spleen, kidney, qi and dampness syndrome. Methods: Sixty patients with diagnostic criteria of CKD stage 3 and TCM syndromes of spleen and kidney qi and dampness stasis syndrome were selected, and the control group was treated with western medicine. The treatment group was treated with oral administration of renal failure on the basis of Western medicine. The two groups were continuous After three courses of treatment, respectively, from the clinical total efficacy, changes in symptoms of traditional Chinese medicine, physical and chemical indicators and other aspects of evaluation indicators. Results: The total effective rate was 77.5% in the treatment group and 35% in the control group. The BUN and Scr in the treatment group decreased obviously and the eGFR increased obviously. In the clinical symptoms, the total symptom score in the treatment group was significantly lower than that in the treatment group Before treatment, the treatment group was significantly better than the control group (P <0.01). Conclusion: Shenshuai I can effectively improve the clinical symptoms, improve renal function and delay the progression of patients with CKD stage 3.